CALYXT INC (CLXT)

US13173L2060 - Common Stock

6.3  +0.33 (+5.53%)

After market: 6.99 +0.69 (+10.95%)

Fundamental Rating

2

Overall CLXT gets a fundamental rating of 2 out of 10. We evaluated CLXT against 592 industry peers in the Biotechnology industry. While CLXT seems to be doing ok healthwise, there are quite some concerns on its profitability. CLXT is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year CLXT has reported negative net income.
In the past year CLXT has reported a negative cash flow from operations.
In the past 5 years CLXT always reported negative net income.
In the past 5 years CLXT always reported negative operating cash flow.

1.2 Ratios

CLXT has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 100.00%, CLXT belongs to the best of the industry, outperforming 99.36% of the companies in the same industry.
In the last couple of years the Gross Margin of CLXT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CLXT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0%

4

2. Health

2.1 Basic Checks

CLXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLXT has been increased compared to 1 year ago.
The number of shares outstanding for CLXT has been reduced compared to 5 years ago.
Compared to 1 year ago, CLXT has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -17.41, we must say that CLXT is in the distress zone and has some risk of bankruptcy.
CLXT has a Altman-Z score of -17.41. This is amonst the worse of the industry: CLXT underperforms 84.16% of its industry peers.
There is no outstanding debt for CLXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.41
ROIC/WACCN/A
WACC7.68%

2.3 Liquidity

CLXT has a Current Ratio of 0.61. This is a bad value and indicates that CLXT is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.61, CLXT is doing worse than 91.68% of the companies in the same industry.
CLXT has a Quick Ratio of 0.61. This is a bad value and indicates that CLXT is not financially healthy enough and could expect problems in meeting its short term obligations.
CLXT's Quick ratio of 0.61 is on the low side compared to the rest of the industry. CLXT is outperformed by 91.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.61

4

3. Growth

3.1 Past

The earnings per share for CLXT have decreased strongly by -289.74% in the last year.
Looking at the last year, CLXT shows a very negative growth in Revenue. The Revenue has decreased by -99.23% in the last year.
CLXT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.99% yearly.
EPS 1Y (TTM)-289.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-678.57%
Revenue 1Y (TTM)-99.23%
Revenue growth 3Y-72.19%
Revenue growth 5Y-20.99%
Revenue growth Q2Q31.25%

3.2 Future

Based on estimates for the next years, CLXT will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.45% on average per year.
CLXT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 138.26% yearly.
EPS Next Y82.92%
EPS Next 2Y36.68%
EPS Next 3Y22.73%
EPS Next 5Y16.45%
Revenue Next Year38.59%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y138.26%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

1

4. Valuation

4.1 Price/Earnings Ratio

CLXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLXT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CLXT's earnings are expected to grow with 22.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.68%
EPS Next 3Y22.73%

0

5. Dividend

5.1 Amount

CLXT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CALYXT INC

NASDAQ:CLXT (5/31/2023, 7:09:09 PM)

After market: 6.99 +0.69 (+10.95%)

6.3

+0.33 (+5.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap31.33M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 100%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.61
Quick Ratio 0.61
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-289.74%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y82.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-99.23%
Revenue growth 3Y-72.19%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y